JP2008509677A5 - - Google Patents

Download PDF

Info

Publication number
JP2008509677A5
JP2008509677A5 JP2007525861A JP2007525861A JP2008509677A5 JP 2008509677 A5 JP2008509677 A5 JP 2008509677A5 JP 2007525861 A JP2007525861 A JP 2007525861A JP 2007525861 A JP2007525861 A JP 2007525861A JP 2008509677 A5 JP2008509677 A5 JP 2008509677A5
Authority
JP
Japan
Prior art keywords
tumors
usa
days
cells
tetramer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007525861A
Other languages
English (en)
Japanese (ja)
Other versions
JP5530065B2 (ja
JP2008509677A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/028895 external-priority patent/WO2006017856A2/en
Publication of JP2008509677A publication Critical patent/JP2008509677A/ja
Publication of JP2008509677A5 publication Critical patent/JP2008509677A5/ja
Application granted granted Critical
Publication of JP5530065B2 publication Critical patent/JP5530065B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007525861A 2004-08-13 2005-08-15 抗生物質耐性欠失ワクチンの作成方法 Expired - Fee Related JP5530065B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60149204P 2004-08-13 2004-08-13
US60/601,492 2004-08-13
PCT/US2005/028895 WO2006017856A2 (en) 2004-08-13 2005-08-15 Methods for constructing antibiotic resistance free vaccines

Publications (3)

Publication Number Publication Date
JP2008509677A JP2008509677A (ja) 2008-04-03
JP2008509677A5 true JP2008509677A5 (enExample) 2008-06-26
JP5530065B2 JP5530065B2 (ja) 2014-06-25

Family

ID=35839990

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007525861A Expired - Fee Related JP5530065B2 (ja) 2004-08-13 2005-08-15 抗生物質耐性欠失ワクチンの作成方法

Country Status (9)

Country Link
US (4) US8906664B2 (enExample)
EP (2) EP1789559B1 (enExample)
JP (1) JP5530065B2 (enExample)
AU (1) AU2005271246A1 (enExample)
CA (1) CA2577306A1 (enExample)
DK (2) DK1789559T3 (enExample)
ES (2) ES2684749T3 (enExample)
PT (2) PT2942391T (enExample)
WO (1) WO2006017856A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
JP2004500405A (ja) * 2000-03-29 2004-01-08 ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
JP2005527240A (ja) * 2002-05-29 2005-09-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 弱毒リステリア種とこれを使用する方法
ES2684749T3 (es) 2004-08-13 2018-10-04 The Trustees Of The University Of Pennsylvania Métodos para construir vacunas sin resistencia a antibióticos
EP1991263B8 (en) * 2006-03-01 2015-02-25 Aduro Biotech Engineered listeria and methods of use thereof
US8277797B2 (en) * 2006-11-22 2012-10-02 The Regents Of The University Of California Interferon-β production modulating Listeria strains and methods for using same
JP2010534058A (ja) * 2007-04-16 2010-11-04 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性のないリステリア菌およびその構築および使用方法
WO2008130551A2 (en) * 2007-04-16 2008-10-30 The Trustees Of The University Of Pennsylvania Antibiotic resistance free listeria strains and methods for constructing and using same
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
ES2741730T3 (es) * 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
JP5539411B2 (ja) 2009-03-04 2014-07-02 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 血管新生因子を含む組成物およびその使用方法
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2498808A4 (en) 2009-11-11 2014-01-08 Advaxis COMPOSITIONS AND METHOD FOR PREVENTING FLUID MUTATIONS IN THE TREATMENT OF TUMORS WITH HER2 / NEW OVEREXPRESSION
WO2012138377A2 (en) 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
EP2825195A4 (en) 2012-03-12 2015-10-07 Advaxis Inc INHIBITION OF SUPPRESSOR CELL FUNCTION AFTER TREATMENT WITH A LISTERIAL VACCINE
MX2016010791A (es) 2014-02-18 2017-04-27 Advaxis Inc Inmunoterapia con multiples objetivos dirigida por biomarcadores.
MA39717A (fr) * 2014-03-05 2017-01-11 Advaxis Inc Procédés et compositions pour accroître le rapport des lymphocytes t effecteurs aux lymphocytes t régulateurs
MA39849A (fr) * 2014-04-24 2017-03-01 Advaxis Inc Souches de listeria utilisées comme vaccin recombinant et procédé de production
US20160228530A1 (en) * 2014-10-14 2016-08-11 The Trustees Of The University Of Pennsylvania Combination therapy for use in cancer therapy
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
EP3313376A2 (en) * 2015-06-26 2018-05-02 Bayer Animal Health GmbH Methods of modulating cytosolic dna surveillance molecules
CN108138123A (zh) * 2015-09-02 2018-06-08 加利福尼亚大学董事会 用于调节李斯特菌属某些种中prfa介导的毒力基因活化的方法和组合物
HK1258860A1 (zh) * 2015-09-15 2019-11-22 Advaxis, Inc. 含有重组李斯特氏菌株的免疫治疗制剂的制作方法
MX2019005685A (es) 2016-11-30 2019-09-04 Advaxis Inc Composiciones inmunogenicas contra mutaciones de cancer recurrentes y metodos de uso de las mismas.
KR102748132B1 (ko) 2017-09-19 2025-01-02 어드박시스, 인크. 박테리아 또는 리스테리아 균주의 동결건조를 위한 조성물 및 방법
CN111349645B (zh) * 2018-12-24 2022-05-17 上海若泰医药科技有限公司 一种提高非整合减毒李斯特菌疫苗安全性的方法
KR102052108B1 (ko) * 2019-08-16 2019-12-04 주식회사 쎌바이오텍 영양요구성 마커를 포함하는 재조합 플라스미드, 이를 포함하는 항암 약물 위장관 전달용 미생물 및 그를 포함하는 항암 약제학적 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US5204252A (en) 1989-02-08 1993-04-20 Henkel Research Corporation Candida tropicalis transformation system
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5922583A (en) 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
US6099848A (en) * 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2004500405A (ja) 2000-03-29 2004-01-08 ザ トラスティーズ オブ ザ ユニバーシティー オブ ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
TWI221854B (en) 2000-05-26 2004-10-11 Anawrahta Biotech Co Ltd Lac shuttle vectors, kit for expression of a heterologous gene and DNA vaccine carrier containing the same
JP2002253253A (ja) 2001-03-01 2002-09-10 Toyobo Co Ltd 新規dna断片及びグラム陰性細菌用新規ベクター
JP2002253212A (ja) 2001-03-02 2002-09-10 Yamaguchi Technology Licensing Organization Ltd 有用酵母の栄養要求性変異株とその育種方法
DE50103240D1 (de) 2001-09-05 2004-09-16 Ferro Gmbh Strahlenhärtbares Edelmetallpräparat, dieses enthaltende Abziehbilder und Verfahren zum Dekorieren
US7425449B2 (en) 2002-04-30 2008-09-16 The Regents Of The University Of California Site specific Listeria integration vectors and methods for using the same
GB0211459D0 (en) 2002-05-18 2002-06-26 Cobra Therapeutics Ltd Plasmid stabilisation in vivo
FI116068B (fi) 2003-09-15 2005-09-15 Fit Biotech Oyj Plc Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi
ES2684749T3 (es) 2004-08-13 2018-10-04 The Trustees Of The University Of Pennsylvania Métodos para construir vacunas sin resistencia a antibióticos
US7855064B2 (en) * 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same

Similar Documents

Publication Publication Date Title
JP2008509677A5 (enExample)
Sewell et al. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
WO2019002444A9 (en) NEW T CELL RECEPTORS AND IMMUNOTHERAPY USING THE SAME
DK1759013T3 (da) Identificering af overflade-associerede antigener til tumordiagnose
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
JP2009515831A5 (enExample)
US20090169582A1 (en) Recombinant lactobacillus and use of the same
WO2006138567A3 (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
CN115348870A (zh) 通用型嵌合抗原受体t细胞及其应用
JP2014139185A5 (enExample)
EP2283847A3 (en) Disease therapy using dying or dead cells
Hu et al. An HLA-A2. 1-transgenic rabbit model to study immunity to papillomavirus infection
CN104371025B (zh) 一种针对宫颈癌具有免疫原性的蛋白及其应用
Macedo et al. Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles
JP2008541776A5 (enExample)
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
CN108823229B (zh) 一种重组Vip3 Aa蛋白的制备方法及其应用
JP2022518807A (ja) グリコシル化したag85aタンパク質を含む結核予防用ワクチン組成物およびその製造方法
KR20040104464A (ko) 종양을 치료하기 위해 사용되는 세포 항원을 코딩하는뉴클레오티드 서열의 캐리어로서 기능하는 미생물
WO2008127450A8 (en) Linear expression cassette vaccines
CN101066991A (zh) 人肿瘤-睾丸抗原hca587的抗原决定簇多肽及其应用
CN102847168B (zh) 一种预防奶牛乳腺炎的核酸疫苗PV-Fn的设计及其构建
CN1708587B (zh) 作为抗恶性疟的潜在疫苗的重组mva株
Meshkat et al. CTL responses to a DNA vaccine encod-ing E7 gene of human papillomavirus type 16 from an Iranian isolate